Simcere Pharma commences second phase of R & D base construction
Shanghai. October 19. INTERFAX-CHINA - New York Stock Exchange-listed Chinese drug firm Simcere Pharmaceutical Group has started the second phase construction of its drug research and development (R & D) base in Nanjing City, local media reported on Oct. 18.
According to Nanjing-based Yangtze Evening News, the second phase construction of the base, located within Nanjing's Xuanwu district, costs more than RMB 100 million ($14.64 million).
This will also be the last phase construction of the R & D base. Upon completion in October 2010, the complex will house 10 divisions, including biopharmaceuticals, chemical compounds, vaccine and contract research, as well as 600 R & D staff.
At present, Simcere Pharma already operates two R & D bases in Beijing and Shanghai municipalities respectively.